| GTO ID | GTC1809 |
| Trial ID | NCT03326336 |
| Disease | Retinitis Pigmentosa |
| Altered gene | ChrimsonR-tdTomato |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | GS030 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa |
| Year | 2017 |
| Country | France|United Kingdom|United States |
| Company sponsor | GenSight Biologics |
| Other ID(s) | GS030_CLIN_001|2017-002204-27 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||
|
|||||||